172 related articles for article (PubMed ID: 33307889)
21. A comparison of patient treatment pathways among multidrug-resistant and drug-sensitive TB cases in Delhi, India: A cross-sectional study.
Sharma N; Bhatnagar A; Basu S; Khanna A; Chopra KK; Banerjee B; Sharma N; Chandra S; Khanna V; Arora R; Babbar N
Indian J Tuberc; 2020 Oct; 67(4):502-508. PubMed ID: 33077051
[TBL] [Abstract][Full Text] [Related]
22. Programmatic challenges in managing multidrug-resistant tuberculosis in Malawi.
Charlie L; Saidi B; Getachew E; Wanjiru CL; Abebe M; Tesfahunei HA; Atim MG; Manyazewal T; Mlera RN
Int J Mycobacteriol; 2021; 10(3):255-259. PubMed ID: 34494563
[TBL] [Abstract][Full Text] [Related]
23. First- and second-line drug resistance patterns among previously treated tuberculosis patients in India.
Paramasivan CN; Rehman F; Wares F; Sundar Mohan N; Sundar S; Devi S; Narayanan PR
Int J Tuberc Lung Dis; 2010 Feb; 14(2):243-6. PubMed ID: 20074419
[TBL] [Abstract][Full Text] [Related]
24. Drug-resistant tuberculosis: An update on disease burden, diagnosis and treatment.
Lange C; Chesov D; Heyckendorf J; Leung CC; Udwadia Z; Dheda K
Respirology; 2018 Jul; 23(7):656-673. PubMed ID: 29641838
[TBL] [Abstract][Full Text] [Related]
25. Addressing the drug-resistant tuberculosis challenge through implementing a mixed model of care in Uganda.
Kasozi S; Kirirabwa NS; Kimuli D; Luwaga H; Kizito E; Turyahabwe S; Lukoye D; Byaruhanga R; Chen L; Suarez P
PLoS One; 2020; 15(12):e0244451. PubMed ID: 33373997
[TBL] [Abstract][Full Text] [Related]
26. "Side effects--part of the package": a mixed methods approach to study adverse events among patients being programmatically treated for DR-TB in Gujarat, India.
Jakasania A; Shringarpure K; Kapadia D; Sharma R; Mehta K; Prajapati A; Kathirvel S
BMC Infect Dis; 2020 Dec; 20(1):918. PubMed ID: 33267826
[TBL] [Abstract][Full Text] [Related]
27. Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China.
Xia H; van den Hof S; Cobelens F; Zhou Y; Zhao B; Wang S; Zhao Y
BMC Infect Dis; 2020 Jan; 20(1):19. PubMed ID: 31910878
[TBL] [Abstract][Full Text] [Related]
28. Multidrug-resistant tuberculosis in the Northern Territory: A 10-year retrospective case series.
Judge D; Krause V
Commun Dis Intell Q Rep; 2016 Sep; 40(3):E334-E339. PubMed ID: 28278406
[TBL] [Abstract][Full Text] [Related]
29. High fluoroquinolone resistance proportions among multidrug-resistant tuberculosis driven by dominant L2 Mycobacterium tuberculosis clones in the Mumbai Metropolitan Region.
Dreyer V; Mandal A; Dev P; Merker M; Barilar I; Utpatel C; Nilgiriwala K; Rodrigues C; Crook DW; ; Rasigade JP; Wirth T; Mistry N; Niemann S
Genome Med; 2022 Aug; 14(1):95. PubMed ID: 35989319
[TBL] [Abstract][Full Text] [Related]
30. Policy changes and the screening, diagnosis and treatment of drug-resistant tuberculosis patients from 2015 to 2018 in Zhejiang Province, China: a retrospective cohort study.
Jiang W; Peng Y; Wang X; Elbers C; Tang S; Huang F; Chen B; Cobelens F
BMJ Open; 2021 Apr; 11(4):e047023. PubMed ID: 33846156
[TBL] [Abstract][Full Text] [Related]
31. Impact of universal drug susceptibility testing and effective management of multidrug-resistant tuberculosis in Taiwan.
Lee PH; Chan PC; Peng YT; Chu PW; Wu MH; Jou R; Yu MC; Lin CJ; Huang YW; Chien ST; Lee JJ; Chiang CY
PLoS One; 2019; 14(4):e0214792. PubMed ID: 30939150
[TBL] [Abstract][Full Text] [Related]
32. Retaining Patients with Drug-Resistant Tuberculosis on Treatment During the COVID-19 Pandemic - Dharavi, Mumbai, India, 2020-2022.
Gomare MD; Bhide S; Deshmukh R; Kaipilyawar S; Puri V; Moonan PK; Khetade DK; Nyendak M; Yeldandi V; Smith JP; Tobias JL; Date A; Joshi R; Kumar R; Ho CS
MMWR Morb Mortal Wkly Rep; 2023 Mar; 72(12):304-308. PubMed ID: 36952291
[TBL] [Abstract][Full Text] [Related]
33. Modelling the effect of short-course multidrug-resistant tuberculosis treatment in Karakalpakstan, Uzbekistan.
Trauer JM; Achar J; Parpieva N; Khamraev A; Denholm JT; Falzon D; Jaramillo E; Mesic A; du Cros P; McBryde ES
BMC Med; 2016 Nov; 14(1):187. PubMed ID: 27855693
[TBL] [Abstract][Full Text] [Related]
34. Survey of tuberculosis drug resistance among Tibetan refugees in India.
Salvo F; Dorjee K; Dierberg K; Cronin W; Sadutshang TD; Migliori GB; Rodrigues C; Trentini F; Di Serio C; Chaisson R; Cirillo DM
Int J Tuberc Lung Dis; 2014 Jun; 18(6):655-62. PubMed ID: 24903934
[TBL] [Abstract][Full Text] [Related]
35. Impact of rapid molecular diagnostic tests on time to treatment initiation and outcomes in patients with multidrug-resistant tuberculosis, Tamil Nadu, India.
Nair D; Navneethapandian PD; Tripathy JP; Harries AD; Klinton JS; Watson B; Sivaramakrishnan GN; Reddy DS; Murali L; Natrajan M; Swaminathan S
Trans R Soc Trop Med Hyg; 2016 Sep; 110(9):534-541. PubMed ID: 27738284
[TBL] [Abstract][Full Text] [Related]
36. Prevalence of drug-resistant pulmonary tuberculosis in India: systematic review and meta-analysis.
Goyal V; Kadam V; Narang P; Singh V
BMC Public Health; 2017 Oct; 17(1):817. PubMed ID: 29041901
[TBL] [Abstract][Full Text] [Related]
37. Rapid molecular diagnostics for multi-drug resistant tuberculosis in India.
Ramachandran R; Muniyandi M
Expert Rev Anti Infect Ther; 2018 Mar; 16(3):197-204. PubMed ID: 29406800
[TBL] [Abstract][Full Text] [Related]
38. Overcoming the health system barriers to early diagnosis and management of multidrug-resistant tuberculosis in a rural setting in North India.
Bashar MA; Aggarwal A; Bhattacharya S
BMJ Case Rep; 2020 Jan; 13(1):. PubMed ID: 31969399
[TBL] [Abstract][Full Text] [Related]
39. Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis.
Pai H; Ndjeka N; Mbuagbaw L; Kaniga K; Birmingham E; Mao G; Alquier L; Davis K; Bodard A; Williams A; Van Tongel M; Thoret-Bauchet F; Omar SV; Bakare N
BMC Infect Dis; 2022 Nov; 22(1):870. PubMed ID: 36414938
[TBL] [Abstract][Full Text] [Related]
40. The Global Fund in China: Multidrug-resistant tuberculosis nationwide programmatic scale-up and challenges to transition to full country ownership.
Wang L; Li R; Xu C; Zhang H; Ruan Y; Chen M; Wang D; Dirlikov E; Du X; Zhao J; Zhao Y; Wang S; Liu Y; Li L; Falzon D; Sun Y; Wang Y; Schwartländer B; Scano F
PLoS One; 2017; 12(6):e0177536. PubMed ID: 28628669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
